Clarient to Announce 2010 First Quarter Financial Results on Thursday, April 29th

ALISO VIEJO, Calif., April 22 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the first quarter ended March 31, 2010 after the stock market closes on Thursday, April 29th.  

Date: Thursday, April 29, 2010

Start Time: 5:00 p.m. EDT

Call-in Number: 1-877-941-1430 (U.S.) / +1-480-629-9667 (International)

Conference ID Number: 4284748

Webcast: www.clarientinc.com/investor

Web Replay: For those unable to participate in the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call, and will be available for one year.

Speakers: Ron Andrews, Vice Chairman and CEO; Michael Pellini, MD, President and COO; Michael Rodriguez, CFO

Format: Presentation of first quarter 2010 financial results followed by Q&A

About Clarient  

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care.  Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides advanced oncology testing and diagnostic services.  Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE™.  Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia and lymphoma. www.clarientinc.com

SOURCE Clarient, Inc.